GH Research (GHRS) Projected to Post Earnings on Thursday

GH Research (NASDAQ:GHRS) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

GH Research Price Performance

NASDAQ GHRS opened at $16.10 on Thursday. The company has a market cap of $837.65 million, a P/E ratio of -21.76 and a beta of 0.99. GH Research has a 12 month low of $7.98 and a 12 month high of $19.51. The company has a 50-day moving average of $14.81 and a 200-day moving average of $13.99.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GHRS. Wolfe Research set a $39.00 price target on shares of GH Research in a research report on Tuesday, January 6th. Wall Street Zen downgraded GH Research from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Canaccord Genuity Group lifted their target price on GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Guggenheim restated a “buy” rating and set a $29.00 price target on shares of GH Research in a research note on Monday, January 5th. Finally, Citigroup restated a “market outperform” rating on shares of GH Research in a report on Tuesday, January 6th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.11.

Hedge Funds Weigh In On GH Research

A number of institutional investors and hedge funds have recently bought and sold shares of GHRS. Virtus Investment Advisers LLC lifted its position in shares of GH Research by 130.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 20,408 shares of the company’s stock worth $259,000 after purchasing an additional 11,539 shares in the last quarter. Trexquant Investment LP acquired a new stake in GH Research during the 4th quarter valued at $696,000. Goldman Sachs Group Inc. grew its holdings in GH Research by 631.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 80,986 shares of the company’s stock valued at $1,029,000 after purchasing an additional 69,911 shares in the last quarter. Citadel Advisors LLC purchased a new stake in GH Research during the 3rd quarter worth $1,350,000. Finally, Boothbay Fund Management LLC lifted its holdings in GH Research by 504.0% in the 3rd quarter. Boothbay Fund Management LLC now owns 83,550 shares of the company’s stock worth $1,195,000 after buying an additional 69,717 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.